Azithromycin 600 Mg Tablets, Fed
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this randomized, single-dose, two-way crossover evaluation is to compare the relative bioequivalence of a test azithromycin formulation (TEVA Pharmaceuticals USA) to an equivalent oral dose of the commercially available azithromycin (Zithromax®, Pfizer, Inc.) in a test population of 24 adult subjects under fed conditions.
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy |
Drug: Azithromycin 600 mg Tablet Drug: Zithromax® 600 mg Tablet |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Bio-equivalence Study Intervention Model: Crossover Assignment Masking: Open Label |
| Official Title: | A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Relative Bioavailability of a Test Tablet Formulation of Azithromycin (600 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Zithromax®, Pfizer, Inc.) in 24 Fed, Healthy, Adult Subjects |
- Cmax - Maximum Observed Concentration - Azithromycin in Plasma [ Time Frame: Blood samples collected over 168 hour period ] [ Designated as safety issue: No ]
- AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Azithromycin in Plasma [ Time Frame: Blood samples collected over 168 hour period ] [ Designated as safety issue: No ]
- AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)- Azithromycin in Plasma [ Time Frame: Blood samples collected over 168 hour period ] [ Designated as safety issue: No ]
| Enrollment: | 24 |
| Study Start Date: | July 2002 |
| Study Completion Date: | August 2002 |
| Primary Completion Date: | August 2002 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Azithromycin
Azithromycin 600 mg tablet (test) dosed in first period followed by Zithromax® 600 mg tablet (reference) dosed in second period
|
Drug: Azithromycin 600 mg Tablet
1 x 600mg, single-dose fed
|
|
Active Comparator: Zithromax®
Zithromax® 600 mg tablet (reference) dosed in first period followed by Azithromycin 600 mg tablet (test) dosed in second period
|
Drug: Zithromax® 600 mg Tablet
1 x 600mg, single-dose fed
|
Detailed Description:
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Sex:Non-smoking Male or Female; similar proportions of each preferred.
- Age: At least 18 years.
- Weight: BMI less than 30.
Qualifying subjects must be in good health and physical condition as determined by medical history, complete physical examination, and laboratory tests, all obtained within four (4) weeks prior to study start. The subject may not have a history of significant past illness expected to affect the investigation. The normal status of subjects will be confirmed by the following procedures:
- Laboratory Tests: hemoglobin, hematocrit, RBC, WBC, differential count, serum electrolytes (Na, K, Cl), fasting blood glucose, BUN, bilirubin, creatinine, AST, ALT, LD, alkaline phosphatase, and urinalysis. HIV, Hepatitis B, Hepatitis C, and drugs of abuse testing will be done for screening purposes only. urine drugs of abuse testing will be repeated at each check-in. Female subjects will have a serum pregnancy test done at screening and a urine pregnancy test prior to each study period at check-in. Laboratory values which are greater than ± 20% of the normal range will not qualify unless specifically accepted (with comment) by the Principal Investigator. Results of HIV, Hepatitis B, Hepatitis C, and drugs of abuse must be negative or non-reactive for the subject to qualify for the study.
- Electrocardiogram: A 12-lead electrocardiogram (ECG) will be obtained for all subjects. The original tracings, plus interpretation, will be included in the case report form packet.
- Subjects must read and sign the Consent Form.
Exclusion Criteria:
- Subjects not complying with the above inclusion criteria must be excluded from the study.
In addition, any one of the conditions listed below will exclude a subject from the study:
- History of treatment for alcoholism, substance abuse, or drug abuse within past 24 months.
- History of malignancy, stroke, diabetes, cardiac, renal or liver disease, or other serious illness.
- History of treatment for asthma within the past five (5) years.
- History of treatment for any gastrointestinal disorder within the past five (5) years.
- History of hepatic function impairment.
- Females who are pregnant or lactating.
- History of hypersensitivity to azithromycin, erythromycin, or any macrolide antibacterial agent.
Conditions upon screening which might contraindicate or require that caution be used in the administration of azithromycin, including:
- Sitting systolic blood pressure below 90 mmHg, or diastolic pressure below 50 mmHg.
- Heart rate less than 50 beats per minute after a 5-minute rest in a seated position.
- Inability to read and/or sign the consent form.
- Treatment with any other investigational drug during the four (4) weeks prior to the initial dosing for this study.
- Subjects who have donated blood within four (4) weeks prior to the initial dosing for this study.
- Subjects who smoke or use tobacco products or are currently using nicotine products (patches, gums, etc.) At least three (4) consecutive months of abstinence is required.
Contacts and Locations| United States, Missouri | |
| Gateway Medical Research, Inc. | |
| St. Charles, Missouri, United States, 63301 | |
| Principal Investigator: | Azber Ansar, M.D. | Cetero Research, San Antonio |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00834132 History of Changes |
| Other Study ID Numbers: | 02184 |
| Study First Received: | January 30, 2009 |
| Results First Received: | May 7, 2009 |
| Last Updated: | September 11, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Teva Pharmaceuticals USA:
|
Bioequivalence Healthy Subjects |
Additional relevant MeSH terms:
|
Azithromycin Anti-Bacterial Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 16, 2013